Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Nemolizumab-ilto

(Nemluvio®)

Nemluvio®

Drug updated on 3/28/2025

Dosage FormInjection (subcutaneous; 30 mg)
Drug ClassInterleukin-31 receptor antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies
  • Indicated for the treatment of adults with prurigo nodularis

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-5]
  • In patients with prurigo nodularis, nemolizumab significantly improved itch response with a Risk Ratio (RR) of 3.52 (95% Confidence Interval [CI]: 2.48 to 5.02, p < 0.00001) and showed higher Investigator’s Global Assessment (IGA) success rates with an RR of 4.40 (95% CI: 2.86 to 6.75, p < 0.00001) compared to control.
  • In atopic dermatitis (AD), nemolizumab significantly reduced pruritus Visual Analog Scale (VAS) scores versus placebo (Weighted Mean Difference [WMD] = -18.86, 95% CI: -27.57 to -10.15, p < 0.001) and lowered Eczema Area and Severity Index (EASI) scores (WMD = -11.76, 95% CI: -20.55 to -2.96, p = 0.009) in the general AD population.
  • In prurigo nodularis, adverse events were slightly more frequent in the nemolizumab group compared to control, but the difference was not statistically significant (RR: 1.11, 95% CI: 0.99 to 1.24).
  • In atopic dermatitis, there was no significant difference in the occurrence of any adverse events between nemolizumab and placebo (RR = 1.03, 95% CI: 0.93 to 1.13, p = 0.593).
  • There is no population type or subgroup information available in the reviewed studies.